Inclusion Criteria:  1. Age 18-85 2. Anterior circulation ischemic stroke symptoms with confirmed occlusion (ICA, M1, or M2) on angiogram and mechanical thrombectomy initiated within 24 hours since last known well 3. a. Patients treated less than 6 hours since last known well with ASPECTS >6. b. Patients treated beyond 6 hours since last known well, CT or MRI perfusion scan showing favorable mismatch profile (Target mismatch profile on CT perfusion or MRI (ischemic core volume is <70ml, mismatch ratio is >1.8 and mismatch volume is >15ml) 4. Post-mechanical thrombectomy with ≤5 device passes and mTICI grade 2b or 2c with persistent occlusion(s) in terminal branches not amenable to MT. 5. Signed informed consent  Exclusion Criteria:  1. Premorbid modified Rankin scale (mRS) score of 4 or greater 2. Presence of any hemorrhage and/or ASPECT score ≤6 on baseline head CT 3. Platelet count <100,000 4. Known bleeding diathesis 5. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency 6. Active anticoagulation treatment with novel oral anticoagulant (NOACs) taken within the last 48 hours, or INR >1.8 7. Patients requiring active treatment with dual antiplatelet agents (e.g. proximal cervical carotid artery stenting) 8. Pregnant or lactating 9. Previous known allergy to TNK 10. Major surgery in past 30 days 11. Patient is on or requires dialysis 12. History of intracranial hemorrhage or serious head trauma at any time 13. Any condition in the opinion of the enrolling physician that would preclude the patient from participating 14. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluation 15. Severe, uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) that is refractory to treatment 16. History of acute ischemic stroke in the last 60 days 17. Presumed septic embolus; suspicion of bacterial endocarditis 18. Suspicion of aortic dissection 19. Intracranial neoplasm 20. Any mass effect 21. Any terminal medical condition with life expectancy less than 6 months 22. Concurrent enrollment in another trial that could confound the results of this study